This work reports the synthesis, characterization and in vitro evaluation of three organometallic triorganotin(IV) complexes bearing a dicarbamido-bis-organosilane benzoate ligand as potential anticancer agents against colorectal cancer cells. The complexes, Sn(IV)-biSi-1, Sn(IV)-biSi-2 and Sn(IV)-biSi-3, differ in the alkyl groups directly bound to the Sn(IV) center (methyl, n-propyl and isopropyl, respectively). Their structures were confirmed by 1H, 13C and 119Sn NMR spectroscopy, FTIR and ESI-MS, supporting monodentate carboxylate coordination and a solvent-dependent Sn(IV) coordination environment. Biological assays in HCT116 cells showed that the final bis-organosilane complexes were markedly more active than their aminobenzoate intermediates and, under several conditions, more effective than cisplatin. Sn(IV)-biSi-2 and Sn(IV)-biSi-3 reduced cell viability to approximately 30% at 0.5 μM after 5 days and to about 11% and 7%, respectively, at 12.5 μM. In repeated-treatment assays, these complexes maintained antiproliferative activity more efficiently than cisplatin, limiting resistance-like cell recovery. Western blot analysis revealed increased γ-H2AX, p53, cleaved caspase-3 and cleaved PARP, indicating DNA damage-associated apoptotic signaling. Overall, these results identify bis-organosilane triorganotin(IV) benzoates, especially Sn(IV)-biSi-2 and Sn(IV)-biSi-3, as promising metal-based anticancer candidates that sustain antiproliferative activity after repeated exposure in colorectal cancer cells and may contribute to strategies aimed at therapy-resistant colorectal tumors.
24 September 2026 in International Journal of Pharmaceutics
Amino-functionalized mesoporous silica nanoparticles (MSNs) were investigated as nanocarriers for two organoheterobimetallic Pt(II)-ferrocene monocations intended for anticancer therapy. Each monocation contains a Pt(II) center bearing two cis-isopropylamine ligands and a p-ferrocenylaniline ligand directly bound to platinum, and the complexes differ only in the counterion (C1, triflate; C2, nitrate). These compounds had been previously synthesized, showing moderate cytotoxic activity against several cancer cell lines after short incubation times, in some cases surpassing cisplatin at high concentrations. Because MSNs are pharmaceutically relevant nanocarriers that can protect metal complexes, modulate exposure and sustain release, this work examines whether their incorporation into amino-functionalized MSNs enhances in vitro activity at low Pt-equivalent concentrations and prolonged exposure times. MSNs were synthesized, amino-functionalized with APTMS and loaded with the Pt(II)-ferrocene complexes predominantly through non-covalent interactions. The resulting formulations preserved spherical mesoporous morphology, displayed homogeneous Pt and Fe distribution, and released Pt in a sustained, pH-dependent manner, with higher release under mildly acidic conditions. Compared with the free complexes, C1@NH2@MSNs and C2@NH2@MSNs improved antiproliferative activity in colorectal, breast and kidney cancer cell lines, with the strongest response in HCT 116 cells. Confocal microscopy confirmed efficient cellular uptake of FITC-labelled MSNs. In zebrafish embryos, C2@NH2@MSNs markedly reduced the systemic and developmental toxicity associated with the free C2 complex and cisplatin. These results support amino-functionalized MSNs as a promising drug-delivery platform for Pt(II)-ferrocene metallodrugs.